CORI Profile
Corium International, Inc. was a biopharmaceutical company that focused on developing transdermal pharmaceutical products. Its lead product was Corplex Donepezil, a once-weekly transdermal patch designed to treat Alzheimer's disease. The patch delivered donepezil, which is an acetylcholinesterase inhibitor, to the bloodstream through the skin. By providing a sustained release of the drug, the patch was intended to improve patient compliance and reduce side effects.
Corium's pipeline also included Corplex Methylphenidate, a transdermal patch for the treatment of attention-deficit/hyperactivity disorder (ADHD), Corplex Memantine, a transdermal patch for the treatment of Alzheimer's disease, and Corplex Oxycodone, a transdermal patch for the management of moderate to severe pain.
In addition to its pharmaceutical products, Corium also provided development and manufacturing services for pharmaceutical and medical device companies. The company's proprietary technologies included its Corplex technology, which allowed for the development of transdermal patches that could deliver a range of drugs, and its MicroCor technology, which enabled the delivery of small molecules through microneedles.
Corium International was founded in 1998 and was headquartered in Menlo Park, California. In 2019, the company was acquired by Gurnet Point Capital, a private investment firm focused on the healthcare industry. As a result of the acquisition, Corium International is no longer publicly traded.
|
